Part II: Chemotherapy for epithelial ovarian cancer - treatment of recurrent disease

被引:122
作者
Harries, M [1 ]
Gore, M [1 ]
机构
[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England
关键词
D O I
10.1016/S1470-2045(02)00847-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For women with advanced ovarian cancer, rates of response to first-line chemotherapy are high but most patients have relapses and become candidates for further chemotherapy. Chemotherapy for recurrence can palliate symptoms, and there is some evidence that it can also improve survival in this clinical situation. Patients who relapse quickly after first-line therapy should not be given the same drugs as were used initially. However, for patients who have longer intervals from treatment to relapse, the rates of response to a rechallenge with platinum are clinically significant. Several cytotoxic drugs have shown activity in patients whose disease has relapsed after therapy with platinum and a taxane; these drugs include topotecan, etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine, altretamine, oxaliplatin, and vinorelbine. Recurrent ovarian cancer is also an important setting in which to test investigational agents with promising activity, such as new platinum compounds, new taxanes, and other cytotoxic agents, as well as non-cytotoxic compounds with novel mechanisms of action.
引用
收藏
页码:537 / 545
页数:9
相关论文
共 78 条
[1]   Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction [J].
AbuRustum, NR ;
Barakat, RR ;
Venkatraman, E ;
Spriggs, D .
GYNECOLOGIC ONCOLOGY, 1997, 64 (03) :493-495
[2]  
[Anonymous], 2010, PHARMACEUTICS
[3]  
AOKI Y, 1991, CANCER RES, V51, P1934
[4]   RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].
BLACKLEDGE, G ;
LAWTON, F ;
REDMAN, C ;
KELLY, K .
BRITISH JOURNAL OF CANCER, 1989, 59 (04) :650-653
[5]   Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer [J].
Bolis, G ;
Scarfone, G ;
Giardina, G ;
Villa, A ;
Mangili, G ;
Melpignano, M ;
Presti, M ;
Tateo, S ;
Franchi, M ;
Parazzini, F .
GYNECOLOGIC ONCOLOGY, 2001, 81 (01) :3-9
[6]  
BOLIS G, 1996, P AN M AM SOC CLIN, V15, P279
[7]   Topotecan for the treatment of advanced epithelial ovarian cancer:: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel [J].
Bookman, MA ;
Malmström, H ;
Bolis, G ;
Gordon, A ;
Lissoni, A ;
Krebs, JB ;
Fields, SZ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3345-3352
[8]   A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum [J].
Brown, JV ;
Peters, WA ;
Rettenmaier, MA ;
Karlan, BY ;
Dillman, RA ;
Smith, MR ;
Drescher, CW ;
Micha, JP .
GYNECOLOGIC ONCOLOGY, 2000, 79 (03) :495-498
[9]  
CALVERT AH, 2001, P AM SOC CLIN ONCOL, V20, pA108
[10]  
CALVERT AH, 2002, P AN M AM SOC CLIN, V21, pA208